Altasciences strengthens its leadership team with Chris Perkin joining the Board of Directors and Marie-Hélène Raigneau stepping into the Chief Executive Officer role to guide the company’s next phase of growth.
Altasciences today announced a significant leadership transition, marking a new chapter in the company’s continued evolution and long-term growth strategy. The organization confirmed the appointment of Chris Perkin to its Board of Directors and the promotion of Marie-Hélène Raigneau to Chief Executive Officer, both effective Tuesday, February 24, 2026. The changes reflect a carefully planned succession process designed to ensure stability, continuity, and sustained excellence in delivering drug development solutions to global biopharmaceutical partners.
The leadership updates come after a year of structured management transition within the company. Over the past 12 months, Altasciences has methodically aligned its executive team to support future expansion while maintaining its strong reputation for scientific rigor, client collaboration, and integrated drug development services. This strategic realignment underscores the organization’s commitment to proactive governance and long-term operational strength.
Chris Perkin’s appointment to the Board of Directors formalizes his ongoing involvement in guiding the company’s strategic direction. With a distinguished career spanning five decades in drug development, Chris has played an instrumental role in shaping Altasciences into a trusted partner for pharmaceutical and biotechnology innovators worldwide. His expertise, industry insight, and deep understanding of clinical research and development processes have contributed significantly to the company’s success and reputation.
Reflecting on the transition, Chris expressed full confidence in the company’s future under new executive leadership. Having worked closely with Marie-Hélène Raigneau for more than 20 years, he emphasized his belief in her ability to guide Altasciences with clarity, determination, and strategic vision. After dedicating 50 years to advancing drug development initiatives, Chris shared that he is stepping down from his executive responsibilities with pride, knowing that the company is well-positioned for sustainable growth and continued innovation.
Marie-Hélène Raigneau’s appointment as Chief Executive Officer represents a natural progression in her longstanding career with the organization. She has served as President since April 2025 and has been a key member of the leadership team for many years. Her tenure has been marked by strong operational leadership, a commitment to client-focused solutions, and a forward-looking approach to innovation within the contract research and drug development sector.
As CEO, Marie-Hélène will assume full responsibility for guiding Altasciences’ global operations, strategic expansion, and continued integration of preclinical and clinical services. Her leadership comes at a pivotal time for the life sciences industry, as pharmaceutical and biotechnology companies increasingly seek agile, integrated development partners capable of accelerating timelines while maintaining high standards of quality and compliance.
Under her direction, Altasciences is expected to continue strengthening its integrated model, which combines early-phase clinical research, manufacturing support, bioanalytical services, and regulatory expertise. This approach enables sponsors to move seamlessly from preclinical stages through early clinical development within a coordinated framework, reducing complexity and enhancing efficiency.
Marie-Hélène’s leadership philosophy centers on collaboration, innovation, and operational excellence. Throughout her career, she has demonstrated a strong ability to align multidisciplinary teams around shared goals, foster a culture of continuous improvement, and respond proactively to evolving client needs. Her appointment signals the company’s confidence in internal leadership development and succession planning.
The management transition over the past year has been intentionally structured to provide continuity and minimize disruption. By gradually shifting responsibilities and ensuring strong communication across teams, Altasciences has maintained operational stability while preparing for its next phase of growth. The Board of Directors has emphasized that this thoughtful transition reflects a broader commitment to responsible corporate governance and strategic foresight.
Industry analysts note that leadership continuity is particularly important in the drug development sector, where long-term partnerships, regulatory compliance, and scientific integrity are paramount. By appointing an experienced internal leader with decades of institutional knowledge, Altasciences reinforces its dedication to maintaining trust with sponsors, regulators, and research collaborators.
In addition to overseeing operational performance, the new leadership team is expected to prioritize innovation in clinical trial design, patient engagement strategies, and data-driven decision-making. As the pharmaceutical landscape continues to evolve—with increasing complexity in biologics, personalized medicine, and rare disease research—contract research organizations must adapt rapidly. Altasciences’ leadership transition positions the company to remain competitive and responsive in this dynamic environment.
Chris Perkin’s continued presence on the Board ensures that institutional knowledge and strategic guidance remain embedded within the organization’s governance structure. His decades of experience in drug development, combined with his mentorship of emerging leaders, provide a valuable foundation as the company moves forward. While stepping away from daily executive duties, his insights will continue to inform high-level decision-making and long-term planning.
For employees, clients, and stakeholders, the announcement represents both continuity and renewal. The combination of seasoned board oversight and energized executive leadership creates a balanced framework for sustainable growth. It also highlights the organization’s commitment to nurturing leadership talent from within, reinforcing a culture of professional development and shared success.
Altasciences’ focus remains firmly on accelerating the development of innovative therapies that improve patient outcomes worldwide. By maintaining strong governance, investing in leadership succession, and fostering collaborative partnerships, the company aims to support the next generation of scientific breakthroughs.
The official statement emphasized that the original language version of the press release remains the legally binding and authoritative document. Any translated versions are provided solely for informational purposes and should be compared with the original text to ensure accuracy. This clarification underscores the importance of precision and transparency in corporate communications, particularly in a global industry where stakeholders operate across multiple jurisdictions.
As Altasciences enters this new phase, the leadership transition reflects both respect for its legacy and confidence in its future. With Chris Perkin contributing at the board level and Marie-Hélène Raigneau leading as Chief Executive Officer, the company is positioned to build on its strong foundation while pursuing strategic growth opportunities in an increasingly complex and innovation-driven healthcare landscape.
